Please login to the form below

Not currently logged in
Email:
Password:

Xeomin receives FDA approval

The FDA has approved Merz Pharmaceuticals' botulinum toxin type A for the treatment of adults with cervical dystonia and blepharospasm

The US Food and Drug Administration (FDA) has approved Merz Pharmaceutical's Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm.

Approval was based on the results of two pivotal US clinical trials involving adult patients diagnosed with either cervical dystonia or blepharospasm. Active comparator studies conducted in Europe, which evaluated Xeomin versus Botox (onabotulinumtoxinA), were also included in the data submitted in support of the registration filing in these conditions.

Jack Britts, president and CEO of Merz Pharmaceuticals commented that this is an important regulatory milestone for Xeomin and is key to establishing the company's neurology business in the US.

"We at Merz understand, and are committed to, addressing the complexities of treating and living with these neurological disorders," Britts said.

Xeomin is the only botulinum toxin that does not require refrigeration prior to reconstitution. Merz believes this attribute will simplify product distribution and storage, and help ensure product integrity at the time of injection.

The drug will be available in 50-unit and 100-unit vials, allowing dosing flexibility for administration.

2nd August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....

Infographics